English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, June 12, 2025
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段
耐赋康(R)与EVER001协同发力 云顶新耀推动肾病治疗进入精准管理新阶段
Monday, June 9, 2025
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑
云顶新耀EVER001亮相ERA 2025 探索原发性膜性肾病治疗新路径
Wednesday, May 7, 2025
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
雲頂新耀宣佈耐賦康(R)獲得中國國家藥品監督管理局完全批准 全面拓展IgA腎病治療人群
云顶新耀宣布耐赋康(R)获得中国国家药品监督管理局完全批准 全面拓展IgA肾病治疗人群
Tuesday, April 22, 2025
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575